TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Down 56.0% in June

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) saw a large decrease in short interest in the month of June. As of June 15th, there was short interest totalling 448,500 shares, a decrease of 56.0% from the May 31st total of 1,020,000 shares. Based on an average daily trading volume, of 1,260,000 shares, the days-to-cover ratio is currently 0.4 days. Approximately 6.9% of the shares of the company are short sold.

Institutional Trading of TransCode Therapeutics

A hedge fund recently bought a new stake in TransCode Therapeutics stock. Virtu Financial LLC acquired a new stake in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned approximately 0.84% of TransCode Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of TransCode Therapeutics in a research note on Wednesday, May 29th.

TransCode Therapeutics Price Performance

RNAZ traded down $0.01 during midday trading on Friday, hitting $1.01. 217,592 shares of the company were exchanged, compared to its average volume of 381,726. The company’s 50 day simple moving average is $1.09 and its 200 day simple moving average is $1.80. TransCode Therapeutics has a 1-year low of $0.42 and a 1-year high of $128.00.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.